Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants

Background The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations.Research design and methods In this phase 2 trial, conducted from 1 December 2021, to 25 July 2023, 392 unvaccinated adults aged ≥18 years were randomized to receive a primar...

Full description

Saved in:
Bibliographic Details
Main Authors: Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Expert Review of Vaccines
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2025.2456231
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832583827069861888
author Guiqiang Wang
Kexin Zhao
Xiuli Zhao
Yimin Cui
Peng He
Tianzuo Zhang
Yanchao Wang
Rui Shi
Yanhua Li
Qian Wang
Yanping Ren
Zhisong Chen
Xuedan Zhao
Zekang Xie
Yufei Liang
Qingyun Tian
Jing Pan
Chao Zhang
Ying Han
Yuyang Dai
Siyang Ni
Yun Zhang
Xinjie Yang
Yongpan Fu
Dongfang Liu
Jing Li
Miaomiao Zhang
Zhongyu Hu
Liangzhi Xie
author_facet Guiqiang Wang
Kexin Zhao
Xiuli Zhao
Yimin Cui
Peng He
Tianzuo Zhang
Yanchao Wang
Rui Shi
Yanhua Li
Qian Wang
Yanping Ren
Zhisong Chen
Xuedan Zhao
Zekang Xie
Yufei Liang
Qingyun Tian
Jing Pan
Chao Zhang
Ying Han
Yuyang Dai
Siyang Ni
Yun Zhang
Xinjie Yang
Yongpan Fu
Dongfang Liu
Jing Li
Miaomiao Zhang
Zhongyu Hu
Liangzhi Xie
author_sort Guiqiang Wang
collection DOAJ
description Background The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations.Research design and methods In this phase 2 trial, conducted from 1 December 2021, to 25 July 2023, 392 unvaccinated adults aged ≥18 years were randomized to receive a primary series of two doses and a booster dose of SCTV01C, a bivalent protein SARS-CoV-2 vaccine.Results Geometric mean titers (GMTs) of neutralizing antibodies (nAb) against live Alpha, Beta, Delta, and Omicron showed 85.4-, 100.0-, 32.1-, and 9.8-fold increase from baseline on 28 days, and 49.4-, 55.3-, 5.7-fold increase against live Alpha, Beta, and Omicron on 90 days after primary series. At Day 28 and Day 90 following the booster dose, GMTs of nAb against Beta, BA.2 and BA.5 variants showed 12.1- and 8.8-, 13.8- and 7.1-, 18.7-, and 11.9-fold of increase from baseline, respectively. Reactogenicity was generally mild, with one adverse event of special interest (AESI) and 9 ≥Grade 3 treatment-related adverse events (TRAEs); all recovered within 3 days.Conclusions SCTV01C, when administered as both a primary series and a booster vaccination, exhibited encouraging sustained immunogenicity against both antigen-matched and antigen-mismatched variants, with no significant safety concerns.Clinical trial registration www.clinicaltrials.gov identifier is NCT05148091.
format Article
id doaj-art-f613b5f17b774955a1f8a718660a3fd0
institution Kabale University
issn 1476-0584
1744-8395
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Expert Review of Vaccines
spelling doaj-art-f613b5f17b774955a1f8a718660a3fd02025-01-28T05:53:53ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952025-12-0124112813710.1080/14760584.2025.2456231Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variantsGuiqiang Wang0Kexin Zhao1Xiuli Zhao2Yimin Cui3Peng He4Tianzuo Zhang5Yanchao Wang6Rui Shi7Yanhua Li8Qian Wang9Yanping Ren10Zhisong Chen11Xuedan Zhao12Zekang Xie13Yufei Liang14Qingyun Tian15Jing Pan16Chao Zhang17Ying Han18Yuyang Dai19Siyang Ni20Yun Zhang21Xinjie Yang22Yongpan Fu23Dongfang Liu24Jing Li25Miaomiao Zhang26Zhongyu Hu27Liangzhi Xie28Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, ChinaHebei Petro China Central Hospital, Langfang, ChinaBeijing Tong Reng Hospital, Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Peking University First Hospital, Beijing, ChinaNational Institutes for Food and Drug Control, Beijing, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaHebei Petro China Central Hospital, Langfang, ChinaBeijing Tong Reng Hospital, Capital Medical University, Beijing, ChinaBeijing Tong Reng Hospital, Capital Medical University, Beijing, ChinaBeijing Tong Reng Hospital, Capital Medical University, Beijing, ChinaBeijing Tong Reng Hospital, Capital Medical University, Beijing, ChinaBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, ChinaBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, ChinaBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, ChinaBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, ChinaBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, ChinaNational Institutes for Food and Drug Control, Beijing, ChinaBeijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, Beijing, ChinaBackground The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations.Research design and methods In this phase 2 trial, conducted from 1 December 2021, to 25 July 2023, 392 unvaccinated adults aged ≥18 years were randomized to receive a primary series of two doses and a booster dose of SCTV01C, a bivalent protein SARS-CoV-2 vaccine.Results Geometric mean titers (GMTs) of neutralizing antibodies (nAb) against live Alpha, Beta, Delta, and Omicron showed 85.4-, 100.0-, 32.1-, and 9.8-fold increase from baseline on 28 days, and 49.4-, 55.3-, 5.7-fold increase against live Alpha, Beta, and Omicron on 90 days after primary series. At Day 28 and Day 90 following the booster dose, GMTs of nAb against Beta, BA.2 and BA.5 variants showed 12.1- and 8.8-, 13.8- and 7.1-, 18.7-, and 11.9-fold of increase from baseline, respectively. Reactogenicity was generally mild, with one adverse event of special interest (AESI) and 9 ≥Grade 3 treatment-related adverse events (TRAEs); all recovered within 3 days.Conclusions SCTV01C, when administered as both a primary series and a booster vaccination, exhibited encouraging sustained immunogenicity against both antigen-matched and antigen-mismatched variants, with no significant safety concerns.Clinical trial registration www.clinicaltrials.gov identifier is NCT05148091.https://www.tandfonline.com/doi/10.1080/14760584.2025.2456231SafetyimmunogenicitySARS-CoV-2multivalent vaccinebooster
spellingShingle Guiqiang Wang
Kexin Zhao
Xiuli Zhao
Yimin Cui
Peng He
Tianzuo Zhang
Yanchao Wang
Rui Shi
Yanhua Li
Qian Wang
Yanping Ren
Zhisong Chen
Xuedan Zhao
Zekang Xie
Yufei Liang
Qingyun Tian
Jing Pan
Chao Zhang
Ying Han
Yuyang Dai
Siyang Ni
Yun Zhang
Xinjie Yang
Yongpan Fu
Dongfang Liu
Jing Li
Miaomiao Zhang
Zhongyu Hu
Liangzhi Xie
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
Expert Review of Vaccines
Safety
immunogenicity
SARS-CoV-2
multivalent vaccine
booster
title Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
title_full Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
title_fullStr Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
title_full_unstemmed Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
title_short Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants
title_sort sustained immunogenicity of bivalent protein covid 19 vaccine sctv01c against antigen matched and mismatched variants
topic Safety
immunogenicity
SARS-CoV-2
multivalent vaccine
booster
url https://www.tandfonline.com/doi/10.1080/14760584.2025.2456231
work_keys_str_mv AT guiqiangwang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT kexinzhao sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT xiulizhao sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yimincui sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT penghe sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT tianzuozhang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yanchaowang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT ruishi sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yanhuali sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT qianwang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yanpingren sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT zhisongchen sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT xuedanzhao sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT zekangxie sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yufeiliang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT qingyuntian sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT jingpan sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT chaozhang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yinghan sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yuyangdai sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT siyangni sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yunzhang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT xinjieyang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT yongpanfu sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT dongfangliu sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT jingli sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT miaomiaozhang sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT zhongyuhu sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants
AT liangzhixie sustainedimmunogenicityofbivalentproteincovid19vaccinesctv01cagainstantigenmatchedandmismatchedvariants